NASDAQ:ACET Adicet Bio Q4 2025 Earnings Results & Report $3.94 -0.05 (-1.25%) Closing price 10/26/2026 04:00 PM EasternExtended Trading$3.93 -0.01 (-0.36%) As of 10/26/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Adicet Bio beat analyst earnings expectations in its Q4 2025 results, released March 12, 2026. The company reported EPS of -$2.94 versus the -$3.23 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 12, 2026TimeBefore Market Opens Adicet Bio EPS ResultsActual EPS-$2.94Consensus EPS -$3.23Beat/MissBeat by +$0.29One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAdicet Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAdicet Bio's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Adicet Bio Q4 2025 Earnings FAQ Did Adicet Bio beat earnings estimates for Q4 2025? Adicet Bio (NASDAQ:ACET) reported earnings of -$2.94 per share for Q4 2025, beating the consensus estimate of -$3.23. The report was announced on Thursday, March 12, 2026. When is Adicet Bio's next earnings date? Adicet Bio's next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Adicet Bio on the company's earnings history page. Adicet Bio Earnings HeadlinesAdicet Bio, Inc. (ACET) - What Are Researchers Saying About This Stock?October 18, 2026 | americanbankingnews.comAdicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street ZenOctober 17, 2026 | americanbankingnews.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time. | Profits Run (Ad)Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Adicet Bio (ACET)September 30, 2026 | theglobeandmail.comAdicet Bio reports positive Prula-cel phase 1 lupus data as pivotal study plans advanceSeptember 28, 2026 | msn.comAdicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis TranscriptSeptember 28, 2026 | seekingalpha.comSee More Adicet Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adicet Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adicet Bio and other key companies, straight to your email. Email Address About Adicet BioAdicet Bio (NASDAQ:ACET) is a clinical-stage biotechnology company developing allogeneic T-cell therapies for the treatment of cancer. The company’s platform is focused on genetically engineered gamma delta T cells, an immune-cell type that can recognize and attack abnormal cells while potentially offering advantages for off-the-shelf cell therapy development. Adicet’s product candidates are designed to incorporate chimeric antigen receptors and other modifications intended to improve tumor targeting, persistence, and activity. Its lead programs have included ADI-001, an investigational allogeneic gamma delta CAR T-cell therapy targeting CD19 for certain B-cell malignancies, including relapsed or refractory large B-cell lymphoma. The company has also pursued additional candidates aimed at hematologic cancers and solid tumors. Founded in 2014 and headquartered in Redwood City, California, Adicet Bio has advanced its programs through collaborations and clinical development activities in the United States and internationally. The company is led by Chief Executive Officer Chen Schor. Its therapies remain investigational and are subject to clinical testing and regulatory review.View Adicet Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings T-Mobile US (10/28/2026)Alphabet (10/28/2026)Alphabet (10/28/2026)Carvana (10/28/2026)eBay (10/28/2026)Garmin (10/28/2026)O'Reilly Automotive (10/28/2026)Equinor ASA (10/28/2026)Phillips 66 (10/28/2026)AON (10/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
